M.D. Anderson Cancer Centre

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia1 trial
• Bladder cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Chronic myeloid leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Follicular lymphoma1 trial
• Mantle cell lymphoma1 trial
• Multiple myeloma1 trial
• Prostate cancer1 trial

Phase

• Phase 1/21 trial
• Phase 41 trial

Status

• Active, not recruiting1 trial
• Terminated1 trial

Lead sponsor

• Clarity Pharmaceuticals Ltd1 trial
• Pharmacyclics Switzerland GmbH1 trial

Running trials

• Active, not recruiting

  Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

  NCT03229200· Phase 4· Pharmacyclics Switzerland GmbH· Source

Closed trials

• Terminated

  64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

  NCT05633160· Phase 1/2· Clarity Pharmaceuticals Ltd· Source